- Company
- GC accelerates global entry…targets China and Vietnam
- by Her, sung-kyu Jul 29, 2024 05:48am
- The GC group accelerating its global market entry after exporting Alyglo to the U.S., seeking to expand its business to China and Vietnam. In particular, it chose to cooperate with China's CR Pharmaceutical Group after selling its Chinese subsidiary, and the company is also seeking to enter Southeast Asia by collaborating with local companies
- Policy
- Daewoong secures generic Xigduo through a transfer
- by Lee, Tak-Sun Jul 29, 2024 05:48am
- Daewoong Pharmaceutical has secured a generic version of the diabetes treatment Xigduo XR Tab (metformin hydrochloride/dapagliflozin propanediol hydrate) through a transfer and acquisition deal. The drug will be covered by reimbursement and introduced to the market in August. With the addition of generic Xigduo XR Tab, Daewoong Pharmaceuti
- Policy
- P3T for new insomnia drug will be conducted in KOR
- by Lee, Hye-Kyung Jul 29, 2024 05:47am
- The Swiss biotechnology company Idorsia will conduct a Phase III clinical trial in Korea for ACT-541468 (daridorexant), its new drug candidate for insomnia. The Ministry of Food and Drug Safety (MFDS) approved Nxera Pharma Korea's application for a "multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase III clin
- Company
- Samsung Bioepis’ 3mth operating profit exceeds last year's
- by Chon, Seung-Hyun Jul 26, 2024 05:47am
- Samsung Bioepis posted the largest Q2 revenue in its history. The company recorded twice as much revenue as in its previous record, and its operating income surpassed what it earned in the entire year last year. This is due to the large influx of milestones, receiving a series of approvals for biosimilars in the U.S. and Europe. According to
- Company
- "Active viral hepatitis treatment can prevent carcinoma"
- by Son, Hyung-Min Jul 26, 2024 05:47am
- "Most individuals affected by viral hepatitis do not have symptoms. They may not be aware of their infection. When individuals realize that they have abnormalities in their body, liver disease has already progressed. It is important to identify and treat patients early in their disease progression to prevent complications related to hepato
- Policy
- KDCA "Will secure budget for domestic mRNA vaccine dev."
- by Lee, Jeong-Hwan Jul 26, 2024 05:47am
- The Korea Disease Control and Prevention Agency (KDCA) announced that they will focus on securing national budget to develop Korea-made mRNA vaccines and secure platforms, supporting up to phase 3 trials. Its vision is to secure domestic mRNA technology based on Japan's case. Japan designated companies that could develop domestic vaccine
- Policy
- Will Rinvoq’s pediatric indication be expanded in KOR?
- by Lee, Hye-Kyung Jul 26, 2024 05:47am
- AbbVie Korea will conduct a clinical trial in Korea to expand the indication of its atopic dermatitis drug Rinvoq (upadacitinib) to children aged 2 to 12 years old. On the 24th, the Ministry of Food and Drug Safety (MFDS) approved AbbVie’s application to initiate a Phase III, open-label, blinded trial (START UP) to compare the safety and
- Company
- Mitsubishi accepts DREC results for Uplizna...nears reimb
- by Eo, Yun-Ho Jul 26, 2024 05:47am
- Mitsubishi Tanabe Pharma’s twice-yearly neuromyelitis optica spectrum disorder (NMOSD) drug Uplizna is headed for reimbursement listing in Korea. According to industry sources, Mitsubishi Tanabe Pharma’s Korea accepted the ‘below the evaluated amount’ condition set by the Health Insurance Review and Assessment Service's Drug Reimburse
- Company
- Guidelines for new obesity drugs must be established
- by Moon, sung-ho Jul 26, 2024 05:46am
- Obesity is projected to impact around 2 billion individuals by 2035. Including overweight, about 4 billion individuals will be affected by obesity, making it a significant global healthcare issue. Following this trend, pharmaceutical and biotech industry is focusing on developing next-generation treatments for obesity. Glucagon-like peptid
- Company
- Antibiotic prescriptions had surged with the pandemic
- by Kim, Jin-Gu Jul 25, 2024 05:51am
- The amount of outpatient antibiotic prescriptions in Korea had changed dramatically during the COVID-19 pandemic. In 2020 and 2021, early stages of the pandemic, antibiotic prescriptions dropped sharply but then surged in 2022. In contrast, the proportion of cephalosporin and quinolone antibiotic prescriptions, which are more powerful than ot
